Previous work from our group has shown that a single intra-myocardial injection of chimeric EFNA1-Fc at the time of ischemia in non-reperfused myocardium lowers cardiomyocyte injury by 50 percent at 4 days post-MI, by reducing necrosis, apoptosis, and inflammatory cell infiltration [1]. Here, EFNA1 is linked to ischemia.